SYNGENE Q3 FY25 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹944 Cr
verified against source
Revenue YoY
11%
reported change
EBITDA
₹284 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Syngene delivered a strong Q3 FY25 with 11% YoY revenue growth to INR 944 crore and 23% EBITDA growth to INR 284 crore, marking a return to growth after two quarters of decline. The 300bps EBITDA margin expansion to 30.1% demonstrates solid operating leverage. Management attributes the recovery to pilot-to-contract conversions with mid and large pharma companies seeking China+One alternatives, plus steady biologics performance in the CDMO segment. The 8-12 week delay in anticipated recovery reflects slower-than-expected stabilization in U.S. biotech funding. Full-year guidance has been revised down to single-digit revenue growth and flat EBITDA, with 9-month revenue up only 2% YoY. CapEx of ~$60M remains on track, with the Stelis biologics facility expected ready in Q4. Key risks include dependence on biotech funding cycles, competitive intensity from global peers, and the need to ramp the newly operational biologics facility. Management expressed confidence in multi-year structural tailwinds from supply chain rebalancing.
Colored figures show movement against the previous available record.
Guidance to track
- After 9M revenue up 2% YoY and Q3 returning to 11% growth, management expects single-digit revenue growth for FY25, down from earlier high single-digit to low double-digit guidance.
- Despite Q3's strong 23% EBITDA growth and margin expansion, 9M EBITDA is flat YoY. Full-year EBITDA guidance remains flat, reflecting first-half weakness.
- Operating EBITDA margins expected around last year's levels in the high 20s range, with Q4 margins continuing the recovery trajectory seen in Q3.
- CapEx program remains on track at approximately $60 million by year-end, with roughly 50% allocated to research services and 25% to biologics (Unit 3 upgrade).
Risks flagged
- Management acknowledged an 8-12 week delay in anticipated U.S. biotech market recovery. Q4 performance guidance assumes continued momentum but faces risk if funding environment remains subdued.
- The Stelis Unit 3 facility becomes operational in Q4 but is pre-revenue as Syngene enters the commercial selling cycle. Utilization ramp and customer acquisition for this large-molecule facility carries execution risk.
- Initial guidance of high single-digit to low double-digit growth has been revised down to single-digit. Analyst (Goldman Sachs) probed whether the miss was external (market timing) or internal (market share loss). Management attributed it to external factors but the repeated downward revisions signal execution pressure.
- Analyst (Fidelity) asked for cost drag from two underutilized facilities (renovation site and API facility). Management declined to provide specifics, leaving opacity on profitability impact from idle capacity costs.
Key quotes
- The rate of stabilization in the biotech funding took longer in the year than what we'd included in our original guidance. I was hopeful that it would stabilize clearly in 2Q, and I think it stabilized more in 3Q.
- Despite challenges faced in the first half year, we expect to close the full year with single-digit revenue growth and a flat EBITDA.
- It's more structural. Here's a good word for you. It's more tectonic. You know, like plate tectonic. It's going in one direction. It's powerful, but it's slow-moving, steady-moving.
Research modules